Aptose Biosciences Inc.

Posters & Presentations

All Poster Presentation
November 7, 2024 Presentation

Aptose Corporate Presentation November 2024

Aptose Corporate Presentation November 2024: View Presentation
July 26, 2024 Presentation

Aptose Corporate Presentation July 2024

Aptose Corporate Presentation July 2024: View Presentation
June 14, 2024 Poster

2024 EHA Poster – Tuspetinib Retains Nanomolar Potency Against AML Cells Engineered to Express the NRAS G12D Mutation or Selected for Resistance to Venetoclax

2024 EHA Poster – Tuspetinib Retains Nanomolar Potency Against AML Cells Engineered to Express the NRAS G12D Mutation or Selected for Resistance to Venetoclax: View Poster
June 14, 2024 Poster

2024 EHA Poster – Safety and Efficacy of Tuspetinib as Monotherapy and Combined with Venetoclax in a Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

2024 EHA Poster – Safety and Efficacy of Tuspetinib as Monotherapy and Combined with Venetoclax in a Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML): View Poster
May 3, 2024 Presentation

Aptose Corporate Presentation May 2024

Aptose Corporate Presentation May 2024: View Presentation
December 26, 2023 Presentation

Aptose Corporate Presentation December 2023

Aptose Corporate Presentation December 2023: View Presentation
December 9, 2023 Presentation

Tuspetinib Oral Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Tuspetinib Oral Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML): View Presentation
October 30, 2023 Presentation

Tuspetinib Clinical Update and KOL Data Review

Tuspetinib Clinical Update and KOL Data Review: View Presentation
October 29, 2023 Poster

2023 ESH Poster – Tuspetinib Oral Myeloid Kinase Inhibitor Creates Synthetic Lethal Vulnerability to Venetoclax

2023 ESH Poster – Tuspetinib Oral Myeloid Kinase Inhibitor Creates Synthetic Lethal Vulnerability to Venetoclax : View Poster